

CarVin versus CarEto - A randomised phase II study of carboplatin and vinorelbine versus carboplatin and etoposide in good performance status small cell lung cancer patients presenting with adverse prognostic factors

Submission date 12/09/2003	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 12/09/2003	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 04/07/2011	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Ernie Marshall

Contact details
Clatterbridge Centre for Oncology
Clatterbridge Road
Bebington
Wirral
United Kingdom
CH63 4JY
+44 0151 334 1155
ernie.marshall@ccotrust.nhs.uk

Additional identifiers

Protocol serial number
N0067120650

Study information

Scientific Title

Study objectives

A randomised phase II study of carboplatin and vinorelbine versus carboplatin and etoposide in good performance status small cell lung cancer patients presenting with adverse prognostic factors.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Cancer: Small cell lung cancer

Interventions

1. Chemotherapy with carboplatin and vinorelbine
2. Chemotherapy with carboplatin and etoposide

Added July 2008: trial stopped because of poor recruitment

Intervention Type

Other

Phase

Phase II

Primary outcome(s)

1. Toxicity
2. Tumour response

Key secondary outcome(s))

Not provided at time of registration

Completion date

08/04/2006

Reason abandoned (if study stopped)

Insufficient personnel

Eligibility

Key inclusion criteria

1. Elderly patients >65 years with good prognosis and Eastern Cooperative Oncology Group (ECOG) p/s <2
2. Confirmed small cell lung cancer not considered eligible for aggressive multimodality therapy

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

08/04/2002

Date of final enrolment

08/04/2006

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Clatterbridge Centre for Oncology

Wirral

United Kingdom

CH63 4JY

Sponsor information

Organisation

Department of Health (UK)

Funder(s)**Funder type**

Government

Funder Name

Clatterbridge Centre for Oncology NHS Trust (UK)

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration